Linsey Philip, MD
Infectious Disease · Fall River, MANPI 1053304469
Payments from drug & device makers
Across 307 payments — averaging $26.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$1K
- Viiv Healthcare Company$907
- AstraZeneca$865
- Novo Nordisk$621
- Johnson & Johnson$528
- AbbVie$446
- plus $3K from 26 others
What the payments were for
- Food & beverage$7,84798%
- Education$1602%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gilead | 50 | $1,200 |
| Viiv Healthcare Company | 34 | $907 |
| AstraZeneca | 16 | $865 |
| Novo Nordisk | 32 | $621 |
| Johnson & Johnson(2 entities) | 19 | $528 |
| AbbVie(2 entities) | 31 | $446 |
| GSK | 10 | $438 |
| Boehringer Ingelheim | 9 | $358 |
| Janssen Products, LP | 5 | $347 |
| Mylan Specialty L.p. | 9 | $317 |
| Merck | 15 | $264 |
| Otsuka America Pharmaceutical, Inc. | 12 | $179 |
| Amarin Pharma, Inc. | 5 | $168 |
| Phathom Pharmaceuticals, Inc. | 8 | $166 |
| Paratek Pharmaceuticals, Inc. | 7 | $154 |
| Bayer | 5 | $131 |
| Edwards Lifesciences | 1 | $122 |
| Regeneron Healthcare Solutions, Inc. | 1 | $119 |
| Teva Pharmaceuticals USA, Inc. | 10 | $113 |
| Sanofi-aventis U.S. LLC | 1 | $110 |
| Inari Medical, Inc. | 1 | $101 |
| Napo Pharmaceuticals Inc | 4 | $51 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $51 |
| Melinta Therapeutics, LLC | 3 | $49 |
| Lilly USA, LLC | 3 | $43 |
| Kowa Pharmaceuticals America, Inc. | 3 | $39 |
| Sunovion Pharmaceuticals Inc. | 2 | $26 |
| Pfizer | 1 | $22 |
| Supernus Pharmaceuticals, Inc. | 1 | $21 |
| Aimmune Therapeutics, Inc. | 1 | $20 |
| Astellas Pharma US Inc | 1 | $17 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$8,007 in reported general payments places this provider in the 75th percentile of 368 infectious disease providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 65 | $287,593 |
| DovatoDolutegravir Sodium/Lamivudine | 80 | $242,838 |
| TriumeqAbacavir/Dolutegravir/Lamivudi | 62 | $242,094 |
| EliquisApixaban | 113 | $98,077 |
| OzempicSemaglutide | 85 | $85,077 |
| JardianceEmpagliflozin | 71 | $72,980 |
| FarxigaDapagliflozin Propanediol | 88 | $65,610 |
| XareltoRivaroxaban | 60 | $57,680 |
| DelstrigoDoravirine/Lamivu/Tenofov Diso | 13 | $47,445 |
| PrezcobixDarunavir/Cobicistat | 18 | $42,866 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 56 | $39,921 |
| TrulicityDulaglutide | 38 | $36,074 |
| JanuviaSitagliptin Phosphate | 21 | $29,236 |
| DescovyEmtricitabine/Tenofov Alafenam | 12 | $28,720 |
| Breo ElliptaFluticasone/Vilanterol | 37 | $22,870 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Viiv Healthcare CompanyDovato, Triumeq | $907 | $484,931142 claims |
| GileadBiktarvy, Descovy | $1,200 | $316,31377 claims |
| Boehringer IngelheimJardiance, Tradjenta, Spiriva Respimat, Stiolto Respimat, Synjardy Xr | $358 | $119,424124 claims |
| Johnson & JohnsonXarelto, Prezcobix | $528 | $100,54678 claims |
| MerckDelstrigo, Januvia, Pifeltro | $264 | $98,48847 claims |
| PfizerEliquis | $22 | $98,077113 claims |
| Novo NordiskOzempic | $621 | $85,07785 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Bevespi Aerosphere | $865 | $77,872111 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta | $438 | $74,631110 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $43 | $57,76358 claims |
| AbbVieLinzess | $446 | $7,78611 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 368 infectious disease providers in Massachusetts.
Other infectious disease in Fall River
- Dan BarouchBoston$35.8M
- Shahin LockmanBoston$7.4M
- Francisco MartyBoston$6.2M
- Stephen WalshBoston$5.4M
- Sophia KooBoston$4.9M
- Jennifer WangWorcester$2.7M
- David SnydmanBoston$2.6M
- Claudia MartorellSpringfield$2.4M
- Yoav GolanBoston$1.8M
- Robert FinbergWorcester$1.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.